PhaseRx (NASDAQ: PZRX) is a biopharmaceutical company that engages in developing a portfolio of mRNA products to correct life-threatening inherited liver diseases in children. Its initial product development focus is on urea cycle disorders, a group of rare genetic diseases that generally present before the age of 12 and are characterized by the body’s inability to remove ammonia from the blood. The company’s i-ERT approach is enabled by its proprietary Hybrid mRNA Technology platform and is applicable to various inherited liver diseases. Its product pipeline includes PRX-OTC for Ornithine Transarbamylase deficiency; PRX-ASL for Argininosuccinate Lyase deficiency; and PRX-ASS1 for Argininosuccinatesynthetase 1 deficiency. For more information, visit the company’s website at www.phaserx
About NetworkNewsWire
NetworkNewsWire (NNW) provides news aggregation and syndication, enhanced press release services and a full array of social communication solutions. As a multifaceted financial news and distribution company with an extensive team of journalists and writers, NNW is uniquely positioned to best serve private and public companies who need to reach a wide audience of investors, consumers, journalists and the general public. NNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.
For more information, visit https://www.networknewswire.com
Please see full disclaimers on the NetworkNewsWire website: http://nnw.fm/Disclaimer
NetworkNewsWire (NNW)
New York, New York
www.networknewswire.com
212.418.1217 Office
Editor@NetworkNewsWire.com
